AstraZeneca to invest Rs 250 crore on expansion of its GCC in India
AstraZeneca India Private Limited (AZIPL), the global capability centre (GCC) of British-Swedish drugmaker AstraZeneca, announced an investment of Rs 250 crore ($30 million) to expand its Global Innovation and Technology Centre (GITC) in Chennai.
The expansion includes adding close to 1,300 job roles focused on driving innovation, enhancing efficiency, and streamlining operations across the company globally.
The facility currently occupies 334,000 square feet of office space at Ramanujan IT City, with plans to add approximately 180,000 square feet over the next six months to accommodate this expansion, creating AstraZeneca’s biggest global capability centre.
The expanded GITC will leverage technologies such as enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics to shape healthcare outcomes.
Since its inception, the GITC in Chennai has evolved from providing traditional information technology support services to becoming an engine of AstraZeneca’s digital journey, driving productivity, simplification, technology delivery, and innovation across the company’s global operations, supporting the delivery of life-changing medicines to patients worldwide.
Including GITC, AstraZeneca employs more than 4000 people in the country and is continuously shaping talent that is skilled, diverse and future ready.
Apart from being a hub for technology as well as research and development, AstraZeneca markets and distributes its innovative portfolio in specialist disease areas
